Erlotinib and Radiation Therapy in Treating Older Patients With Stage I, Stage II, Stage III, or Stage IV Esophageal Cancer

Part of paid clinical trials in Buffalo, New York.

Sponsor
Roswell Park Cancer Institute
Study ID
NCT00524121
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
65 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

  • erlotinib hydrochloride — DRUG
    Oral
  • immunohistochemistry staining method — OTHER
    Correlative Study
  • radiation therapy — RADIATION
    Radiation Treatment

Study Details

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving erlotinib together with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving erlotinib together with radiation therapy works in treating older patients with stage I, stage II, stage III, or stage IV esophageal cancer.

Key Dates

First listed
Sep 3, 2007
Start date
Mar 31, 2006
Status verified
Mar 2016
Primary completion
May 31, 2010
Completion
Oct 31, 2011

Study Design

Enrollment
22 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Oral Erlotinib
    Patients receive oral erlotinib hydrochloride once daily for 1 year

Primary Outcome Measure

Overall Survival [ Time Frame: 5 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
Roswell Park Cancer InstituteBuffaloNew York14263-0001-

Find similar trials in Buffalo, NY

By condition
Esophageal cancer
By specialty
OncologyGI oncology
By research site
Roswell Park Cancer Institute· Buffalo, NY

Related Studies